Denali Therapeutics (DNLI) Interest & Investment Income (2023 - 2026)

Denali Therapeutics (DNLI) has reported Interest & Investment Income for 4 consecutive years, with $8.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest & Investment Income fell 29.34% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $39.2 million (down 36.08% YoY), while the FY2025 annual figure was $42.9 million, down 33.62% from the prior year.
• Interest & Investment Income steadied at $8.9 million in Q1 2026 per DNLI's latest filing, from $8.9 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $17.6 million in Q2 2024 and bottomed at $8.9 million in Q1 2026.
• Historically, Interest & Investment Income has averaged $12.9 million across 4 years, with a median of $12.9 million in 2023.
• Annual changes were most pronounced in 2024 — Interest & Investment Income surged 44.22% — and 2025, when it sank 41.18%.
• Denali Therapeutics' Interest & Investment Income stood at $13.1 million in 2023, then increased by 15.48% to $15.2 million in 2024, then tumbled by 41.18% to $8.9 million in 2025, then slipped by 0.09% to $8.9 million in 2026.
• Business Quant data shows DNLI's Interest & Investment Income at $8.9 million in Q1 2026, $8.9 million in Q4 2025, and $10.5 million in Q3 2025.